Pyxis Oncology, Inc. financial data

Symbol
PYXS on Nasdaq
Industry
Pharmaceutical Preparations
Location
321 Harrison Avenue, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 756 % -24.4%
Debt-to-equity 27.5 % +33.3%
Return On Equity -39 % +35.9%
Return On Assets -30.6 % +39.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58.1 M shares +57.2%
Common Stock, Shares, Outstanding 58.8 M shares +59.3%
Entity Public Float 97 M USD +26.1%
Common Stock, Value, Issued 59 K USD +59.5%
Weighted Average Number of Shares Outstanding, Basic 51.3 M shares +45.1%
Weighted Average Number of Shares Outstanding, Diluted 51.3 M shares +45.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 16.1 M USD
Cost of Revenue 475 K USD
Research and Development Expense 50.7 M USD -34.9%
General and Administrative Expense 31.8 M USD -9.36%
Operating Income (Loss) -66.8 M USD +40.9%
Nonoperating Income (Expense) 9.04 M USD +103%
Net Income (Loss) Attributable to Parent -57.8 M USD +46.8%
Earnings Per Share, Basic -1.37 USD/shares +57.5%
Earnings Per Share, Diluted -1.37 USD/shares +57.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28 M USD -47.3%
Marketable Securities, Current 129 M USD +34%
Cash, Cash Equivalents, and Short-term Investments 157 M USD +5.16%
Accounts Receivable, after Allowance for Credit Loss, Current 8 M USD
Other Assets, Current 305 K USD -19.9%
Assets, Current 172 M USD +10.4%
Property, Plant and Equipment, Net 11.3 M USD -13.9%
Operating Lease, Right-of-Use Asset 12.8 M USD -5.05%
Intangible Assets, Net (Excluding Goodwill) 23.7 M USD
Other Assets, Noncurrent 449 K USD
Assets 220 M USD +20.5%
Accounts Payable, Current 2.29 M USD -43%
Employee-related Liabilities, Current 5.22 M USD +23.1%
Accrued Liabilities, Current 10.8 M USD +70.2%
Contract with Customer, Liability, Current 7.66 M USD
Liabilities, Current 14.1 M USD +21.9%
Deferred Income Tax Liabilities, Net 2.16 M USD
Operating Lease, Liability, Noncurrent 19.8 M USD +3.78%
Liabilities 36.1 M USD +17.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -60 K USD -109%
Retained Earnings (Accumulated Deficit) -289 M USD -25%
Stockholders' Equity Attributable to Parent 184 M USD +21%
Liabilities and Equity 220 M USD +20.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.7 M USD +22.8%
Net Cash Provided by (Used in) Financing Activities 57.5 M USD
Net Cash Provided by (Used in) Investing Activities -18.5 M USD +81.4%
Common Stock, Shares Authorized 190 M shares 0%
Common Stock, Shares, Issued 58.8 M shares +59%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 18.3 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 29.4 M USD -46%
Deferred Tax Assets, Valuation Allowance 120 M USD +107%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 127 M USD +107%
Operating Lease, Liability 21.3 M USD +12.7%
Depreciation 1.8 M USD +157%
Payments to Acquire Property, Plant, and Equipment 237 K USD -94.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -58.6 M USD +45.7%
Lessee, Operating Lease, Liability, to be Paid 32.3 M USD -7.05%
Property, Plant and Equipment, Gross 15.5 M USD +19.1%
Operating Lease, Liability, Current 1.02 M USD -15.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.28 M USD +2.18%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.19 M USD +24.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.9 M USD -14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.38 M USD +2.21%
Deferred Tax Assets, Operating Loss Carryforwards 67.6 M USD +415%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 2 M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.47 M USD +2.18%
Operating Lease, Payments 1.1 M USD +450%
Additional Paid in Capital 474 M USD +23.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.12 M USD +487%
Deferred Tax Assets, Net of Valuation Allowance 7.62 M USD +107%
Share-based Payment Arrangement, Expense 16.4 M USD -5.32%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%